MAINZ BIOMED N.V.

MAINZ BIOMED N.V. is a molecular genetics diagnostic company specializing in the early detection of cancer. Headquartered in Mainz, Germany, the company develops market-ready molecular genetic diagnostic solutions for life-threatening conditions, with a focus on non-invasive, stool- and blood-based screening tests that utilize real-time Polymerase Chain Reaction (PCR) multiplex detection of molecular-genetic biomarkers. The company operates in one segment: genetic diagnostic testing. Mainz Biomed's flagship commercial product is ColoAlert®, an accurate, non-invasive, and easy-to-use early-detection diagnostic test for colorectal cancer (CRC). ColoAlert® is a DNA-based stool test marketed across Europe and is undergoing clinical studies for U.S. regulatory approval. The company is also developing PancAlert, an early-stage pancreatic cancer screening test based on real-time PCR multiplex detection of molecular-genetic biomarkers in blood and stool samples. Additionally, Mainz Biomed's product portfolio includes GenoStrip, a platform technology for detecting pathogens in environments on a molecular genetic basis. Mainz Biomed emphasizes integrating proprietary mRNA biomarkers and algorithms, including AI-assisted modeling, into its projects. The company partners with diagnostic laboratories, distributors, and digital health platforms to distribute tests, perform laboratory analysis, and integrate screening into healthcare pathways. Mainz Biomed is listed on the Nasdaq Capital Market under the ticker symbol MYNZ. Sources: [1] https://www.stocktitan.net/overview/MYNZ/ [2] https://www.bitget.com/wiki/mainz-biomed-stock [3] https://fintel.io/s/us/mynz [4] https://www.alphaspread.com/comparison/nasdaq/mynz/vs/indx/gspc [5] https://mainzbiomed.com/mainz-biomed-announces-6-0-usd-million-private-placement-and-strategic-update/ [6] https://mainzbiomed.com/mainz-biomed-partners-with-liquid-biosciences-to-harness-the-power-of-artificial-intelligence-ai-to-develop-next-generation-colorectal-screening-test/ [7] https://www.barchart.com/stocks/quotes/MYNZ/profile [8] https://www.marketbeat.com/originals/2-small-cap-biotechs-that-could-reward-patient-investors/